Iscaffpharma

Iscaffpharma is a Swedish biotechnology company specializing in advanced 3D cell culture systems for oncology drug discovery and personalized medicine. The company utilizes its proprietary Patient-Derived Scaffold (PDS) technology, which involves decellularizing human tumor tissue to create a natural extracellular matrix for testing drug efficacy. This platform allows for a more accurate representation of the human tumor microenvironment compared to traditional 2D cultures or animal models. Iscaffpharma provides contract research services to pharmaceutical companies and academic institutions to improve the predictive value of preclinical drug screening. Their focus is on identifying effective treatments for solid tumors, including breast and pancreatic cancers.